DUBLIN, October 12, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Molecular Diagnostics Market - Focus on Infectious Diseases (HPV/Chlamydia/Gonorrhea) & Genetic Testing (HLA) - Industry Outlook 2022" report to their offering.
The market has burgeoned in span of 25 years. It is further poised to reach new heights by breaching US$ 11 billion mark by 2022 by growing at a CAGR of 9.2% in the forecasted period 2016-22.
Molecular diagnostics is used for detecting patient's susceptibility to a disease by tests for detecting and characterizing pathogenic mutations in DNA and RNA samples. It is the most dynamic segment of the global in vitro diagnostics market, given the advantages of precise genetic information over traditional tests. Molecular diagnostics in healthcare has been disseminating around the world at a robust growth rate due its unique ability to unlock molecular information of patients.
In terms of market structure, molecular diagnostics industry is classified into three broad categories - clinical infectious disease, genomics and blood donor screening. The clinical infectious disease segment has two sub-segments: virology and bacteriology tests. The genomics segment is further sub-divided into genetic diseases and disorders, cancer testing, HLA testing, and pharmacogenetic testing. Infectious diseases are the largest segment of molecular diagnostics market.
Growth of the industry is fuelled by prevalence of reproductive infectious diseases such as Chlamydia and Gonorrhea, surge in various types of oncology diagnostics, ageing population and government's mandate on regular screening of HPV and CT/NG. However, complex regulatory framework and lack of clarity on reimbursement are the major factors restraining the growth of the molecular diagnostics market. Key trends prevailing in the industry includes rise in number of strategic industry alliances and use of Next Generation Sequencing (NGS) in clinical molecular diagnostics.
The report provides information on the current scenario, detailed market outlook of the molecular analysis market segments such as Infectious diseases with focus on Human Papilloma virus (HPV) in virology segment and Chlamydia and Gonorrhoea in bacteriology segment. It further analyzes genomics testing market with focus on Human Leukocyte Antigen (HLA) testing. Lastly, Blood Donor Screening market is analysed in the report. Future forecasts on all prominent application areas of the industry till 2022 is also provided in the report. Furthermore, key industry players have been prudently analysed in the competitive landscape section of the report in order to provide key comparative insights.
Major industry players operating in the market include Roche Holding AG, Novartis AG, Hologic Inc, Abbott Diagnostics, Becton Dickinson and Qiagen NV, among others. Roche Holdings, Novartis AG, Hologic Inc and Qiagen NV are profiled herein based on attributes such as business overview, product segments, financial and business strategies.
It also compiles performance comparison of aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in global molecular diagnostics market.
Key Topics Covered:
1. Executive Summary
2. Research Methodology
3. Introduction
4. Molecular Diagnostic Market
5. Global Molecualr Diagnostics Market Segmentation
6. Global Molecular Diagnostics Market Dynamics
7. Competitive Landscape
8. Company Profiles
- Hologic Inc
- Novartis AG
- Qiagen NV
- Roche Holdings
For more information about this report visit http://www.researchandmarkets.com/research/nl5tnm/global_molecular
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
